 ATLANTA, GA, March 25, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. GOVX, a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2019 and provided an update on its corporate development progress. This was combined with tough capital restructuring decisions that, while painful at the time, have now resulted in GeoVax being better positioned for future financing efforts in support of our programs and increasing shareholder value. 